Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

@inproceedings{Evans2010PhaseID,
  title={Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.},
  author={T. R. Jeffry Evans and Colin R Lindsay and Emily Chan and B. Tait and S A Michael and Sharon Day and Anthony W. Stephens and Andreas Franke and Srinivasu Poondru and I. S. Puzanov},
  year={2010}
}
2531 Background: OSI-906 is a potent inhibitor of IGF-1R and IR tyrosine kinase activity. Increased IGF-1R activity is observed in human malignancies and implicated in resistance to chemotherapy. Methods: Patients with advanced cancer received escalating doses of OSI-906. Study objectives included determination of MTD and evaluation of safety, pharmacokinetics (PK), pharmacodynamics (PD), and tumor response. Results: 57 pts have been treated (37M/20F, median age 59 yrs) at 10–450 mg QD and at… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

The Insulin Receptor: A New Target for Cancer Therapy

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Insulin-like growth factor: current concepts and new developments in cancer therapy.

VIEW 1 EXCERPT
CITES BACKGROUND